Bristol Myers Squibb (CELG-RI) EBT Margin Growth (3y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) EBT Margin Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -265.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 636.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3,137.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 625.00 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -10.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 443.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -15,548.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -6,936.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -2,347.00 |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 1,494.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,494.00 |
| Mar 31, 2026 | 377.00 |
| Dec 31, 2025 | -454.00 |
| Sep 30, 2025 | 579.00 |
| Jun 30, 2025 | -202.00 |
| Mar 31, 2025 | 1,204.00 |
| Dec 31, 2024 | -1,408.00 |
| Sep 30, 2024 | -446.00 |
| Jun 30, 2024 | -273.00 |
| Mar 31, 2024 | -11,991.00 |
| Dec 31, 2023 | 10,901.00 |
| Sep 30, 2023 | -193.00 |
| Jun 30, 2023 | 50.00 |
| Mar 31, 2023 | 2,725.00 |
| Dec 31, 2022 | 1,792.00 |
| Sep 30, 2022 | -277.00 |
| Jun 30, 2022 | -1,184.00 |
| Mar 31, 2022 | -1,895.00 |
| Dec 31, 2021 | -969.00 |
| Sep 30, 2021 | -1,952.00 |